Y. Tu

Development of a STEAP1-targeted prostate cancer specific antibody drug conjugate platform with immunostimulatory properties

Background: Patients with prostate cancer who develop androgen pathway modulation resistant (APMR) disease face lethal outcomes despite advances in androgen receptor-pathway inhibitors, chemotherapy, and PSMA-directed radioligands. Antibody-drug conjugates (ADCs) have demonstrate...